Compare · GLP-1 agonist
Ecnoglutide vs Survodutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Survodutide | |
|---|---|---|
| Evidence | 7/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (its development name is XW003) is an injectable drug for type 2 diabetes and weight loss. It belongs to the same broad family of medicines as semaglutide — the GLP-1 receptor agonists (drugs that copy a natural gut hormone to lower blood sugar and curb appetite). Two things make it…
Survodutide
Survodutide (its lab code is BI 456906) is an experimental injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has more real human research behind it than most peptides sold online, including several carefully run trials that compared it against a placebo (a…